{"created":"2023-07-27T06:44:18.161260+00:00","id":34480,"links":{},"metadata":{"_buckets":{"deposit":"f5b077b1-b10c-46ad-be28-3e4eca2eea1a"},"_deposit":{"created_by":3,"id":"34480","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"34480"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00034480","sets":["2812:2813:2819"]},"author_link":["27554","86"],"item_9_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2015-05-21","bibliographicIssueDateType":"Issued"},"bibliographicPageStart":"6p.","bibliographicVolumeNumber":"2011-04-28 – 2015-03-31","bibliographic_titles":[{"bibliographic_title":"平成26(2014)年度 科学研究費補助金 基盤研究(C) 研究成果報告書"},{"bibliographic_title":"2014 Fiscal Year Final Research Report","bibliographic_titleLang":"en"}]}]},"item_9_creator_33":{"attribute_name":"著者別表示","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{}],"nameIdentifiers":[{},{}]}]},"item_9_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"ラット及びヒト肝細胞を用いたゲムシタビンの取り込み実験やラットの肝潅流実験、ヒト試験により、800 mg/SLV以下の投与量では、クレオシドトランスポーターENT2を介した低親和性の肝取り込みの飽和が回避でき、膵癌肝転移に対する術後肝動注化学療法が早期に開始できる可能性が示された。また、腎機能低下患者における抗MRSA薬リネゾリドの体内動態と血小板減少に関しては、リネゾリドおよび代謝物の血中濃度がともに腎機能障害が高度になるほど上昇し、血小板減少率も上昇する傾向が確認できた。さらに、経腸栄養剤長期投与によって小腸や肝臓のトランスポーターや代謝酵素の発現が変動することが示された。","subitem_description_type":"Abstract"},{"subitem_description":"We investigated hepatic uptake of gemcitabine (GEM) in rat and human. The uptake mechanism involved high- and low-affinity saturable components with Km values of micromolar and millimolar order, respectively. Our results suggested that the hepatic extraction of GEM is predominantly mediated by the low-affinity nucleoside transporter ENT2 at clinically relevant hepatic concentrations of GEM, the uptake would not be completely saturated. This is critical for hepatic arterial infusion (HAI), because saturation of hepatic uptake would result in a marked increase of GEM concentration, abrogating the advantage of HAI over i.v. administration in terms of severe adverse events. We investigated pharmacokinetics of linezorid (LZD) in rat and human. The incidence of thrombopenia was increased according to the increase of plasma concentration of LZD. We also found that long-term enteral nutrition affected that the expression of transporters and metabolic enzymes in the liver and small intestine.","subitem_description_type":"Abstract"}]},"item_9_description_22":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"研究課題/領域番号:23590173, 研究期間(年度):2011-04-28 – 2015-03-31","subitem_description_type":"Other"},{"subitem_description":"出典：研究課題「副作用マネジメントと毒性回避のための臨床薬物動態研究出」課題番号23590173\n（KAKEN：科学研究費助成事業データベース（国立情報学研究所）） \n（https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-23590173/23590173seika/)を加工して作成","subitem_description_type":"Other"}]},"item_9_description_5":{"attribute_name":"提供者所属","attribute_value_mlt":[{"subitem_description":"金沢大学附属病院","subitem_description_type":"Other"}]},"item_9_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.24517/00034467","subitem_identifier_reg_type":"JaLC"}]},"item_9_relation_28":{"attribute_name":"関連URI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/search/?qm=40262589"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/search/?qm=40262589","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23590173/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23590173/","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-23590173/23590173seika/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-23590173/23590173seika/","subitem_relation_type_select":"URI"}}]},"item_9_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-10-05"}],"displaytype":"detail","filename":"HO-PR-SAI-Y-kaken 2015-6p.pdf","filesize":[{"value":"271.7 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"HO-PR-SAI-Y-kaken 2015-6p.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/34480/files/HO-PR-SAI-Y-kaken 2015-6p.pdf"},"version_id":"ce861222-b3de-4d9c-adba-d3ab0d031528"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"副作用マネジメントと毒性回避のための臨床薬物動態研究","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"副作用マネジメントと毒性回避のための臨床薬物動態研究"},{"subitem_title":"Clinical pharmacokinetic study for management of drug side effects","subitem_title_language":"en"}]},"item_type_id":"9","owner":"3","path":["2819"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-10-05"},"publish_date":"2017-10-05","publish_status":"0","recid":"34480","relation_version_is_last":true,"title":["副作用マネジメントと毒性回避のための臨床薬物動態研究"],"weko_creator_id":"3","weko_shared_id":3},"updated":"2023-07-27T10:46:16.041933+00:00"}